For how we live.
In a study of 750 women, those with 'low' ovarian-reserve hormones were no less likely to conceive. Professional guidance says the test shouldn't be used to counsel women who aren't already infertile.
23andMe's cleared BRCA report reads 3 of more than 1,000 mutations, so a negative result is not the all-clear it looks like — and the firm's bankruptcy has put customers' genetic data in play.
Researchers searched in four languages across three engines. One in ten clinics said it would prescribe testosterone to men with normal levels; one in five claimed it cuts cardiovascular risk.
A systematic review screened 3,857 records and found three eligible studies, every one produced by a US commercial provider and every one at critical risk of bias.
An audit of 17 manufacturers' privacy policies found transparency the weakest area, with wide variation between brands. The data these devices generate largely falls outside HIPAA and GDPR's clinical protections.
The agency announced an intent to restrict GLP-1 active ingredients destined for non-approved compounded drugs, and warned that seizure and injunction are on the table without further notice.